Mitomycin-C suppresses mucus secretion in an ileal neobladder rat model
- Authors:
- Weiwei Fan
- Yang Yu
- Junjie Shu
- Hao Ming
- Weiping Li
- Zhilu Fan
View Affiliations
Affiliations: Dalian Medical University, Dalian, Liaoning 116085, P.R. China, Department of Urinary Surgery, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China
- Published online on: May 28, 2015 https://doi.org/10.3892/etm.2015.2529
-
Pages:
598-602
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the present study was to investigate the mucus secretion status of mature goblet cells following the application of mitomycin‑C (MMC) in ileal neobladder rat models. Bladder substitution models were established in Sprague Dawley rats, which had been divided into five groups, namely the control (sham), normal saline (NS), high‑dose MMC (HMMC), low‑dose MMC (LMMC) and dehydrated alcohol (DA) groups. To evaluate the total protein concentration and level of sialic acid following the therapy, urine from the rats in each group was collected on days 8, 11 and 14. In addition, to observe the variances between mucus secretion and the ileum goblet cells, immunohistochemistry and hematoxylin and eosin staining were conducted in the different groups on day 17. The results indicated that the ileal neobladder mucosas in the MMC groups were clearly undamaged, as compared with the DA group. Furthermore, the MMC and DA groups were shown to inhibit the proliferation of goblet cells. The concentration of protein and sialic acid in the LMMC group was found to be lower compared with the NS group, while the concentration in the HMMC group was considerably lower. In conclusion, HMMC was demonstrated to evidently reduce the mucin and sialic acid concentration in the urine, without visible damage to the ileal neobladder mucus membrane. Therefore, MMC may provide a novel therapeutic approach for the treatment of certain bladder conditions.
View References
|
1
|
Kashif KM and Holmes SA: The use of small
intestine in bladder reconstruction. Int Urogynecol J Pelvic Floor
Dysfunct. 9:275–280. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun X, Song M, Bai R, Cheng S, Xing Y,
Yuan H, Wang P and Zhou L: Ileal interposition surgery-induced
improvement of hyperglycemia and insulin resistance in
Goto-Kakizaki rats by upregulation of TCF7L2 expression. Exp Ther
Med. 5:1511–1515. 2013.PubMed/NCBI
|
|
3
|
Hautmann RE, de Petriconi RC and Volkmer
BG: Lessons learned from 1,000 neobladders: The 90-day complication
rate. J Urol. 184:990–994. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu Yang: The experimental studies of
anti-tumor agents to intestinal mucus secretion in vitro.
(unpublished PhD thesis)Dalian Medical University2006, (In
Chinese).
|
|
5
|
Demirbilek S, Uğuralp S, Gürbüz N, Sezgin
N and Kirimlioĝlu H: The use of silver nitrate for chemical
de-epithelialization and urothelialization of intestine in a rabbit
model of augmentation cystoplasty. Urol Res. 31:236–241. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leknes IL: Histochemical study on the
intestine goblet cells in cichlid and poecilid species (Teleostei).
Tissue Cell. 42:61–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khorrami MH, Salehi P, Nouri-Mahdavi K,
Ghalamkari A and Tadayyon F: Dramatic effect of a somatostatin
analogue in decreasing mucus production by the intestinal segment
after enterocystoplasty. J Urol. 180:2501–2503. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang T and Zhou X: Clinical application
of expectorant therapy in chronic inflammatory airway diseases
(Review). Exp Ther Med. 7:763–767. 2014.PubMed/NCBI
|
|
9
|
Falke G, Caffaratti J and Atala A: Tissue
engineering of the bladder. World J Urol. 18:36–43. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Loeffler M, Birke A, Winton D and Potten
C: Somatic mutation, monoclonality and stochastic models of stem
cell organization in the intestinal crypt. J Theor Biol.
160:471–491. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen G-J, Datta AK, Izumi M, Koeller KM
and Wong C-H: Expression of α2, 8/2, 9-polysialyltransferase from
Escherichia coli K92. Characterization of the enzyme and its
reaction products. J Boil Chen. 274:35139–35146. 1999. View Article : Google Scholar
|
|
12
|
Levine MJ, Aguirre A, Hatton MN and Tabak
LA: Artifical salivas: Present and future. J Dent Res. 66:693–698.
1987.PubMed/NCBI
|
|
13
|
Matsuo K, Ota H, Akamatsu T, Sugiyama A
and Katsuyama T: Histochemistry of the surface mucous gel layer of
the human colon. Gut. 40:782–789. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baylin SB: Reversal of gene silencing as a
therapeutic target for cancer-roles for DNA methylation and its
interdigitation with chromatin. Novartis Found Symp. 259:226–233.
2004.PubMed/NCBI
|
|
15
|
Ozdemir F, Altinisik J, Karateke A,
Coksuer H and Buyru N: Methylation of tumor suppressor genes in
ovarian cancer. Exp Ther Med. 4:1092–1096. 2012.PubMed/NCBI
|
